Loading...
•
Mar 31
Quantum-Si Q1 2025 Earnings Report
Quantum-Si reported higher revenue in Q1 2025 and delivered key product launches despite continued operating losses.
Key Takeaways
Quantum-Si achieved 84% YoY revenue growth in Q1 2025 with the successful launch of Platinum Pro units and ongoing investment in proteomics R&D. Operating expenses increased modestly as the company maintained focus on commercialization and product development.
Revenue grew 84% year-over-year, reaching $842K.
Net loss narrowed slightly to $19.2M from $19.5M last year.
Launched and delivered first Platinum Pro units.
Maintained strong liquidity with $232.6M in cash and securities.
Quantum-Si
Quantum-Si
Quantum-Si Revenue by Segment
Revenue by Segment
Product Revenue
CapyFin.comService Revenue
CapyFin.com Forward Guidance
Quantum-Si reaffirms progress on product roadmap and sufficient cash runway through H2 2027.
Positive Outlook
- Platinum Pro launched and shipping to customers.
- v4 Sequencing Kit on track for Q3 2025 launch.
- Proteus system expected by end of 2025.
- Cash and investments total $232.6M as of Q1 end.
- Expanded international distribution to 23 partners.
Challenges Ahead
- Net losses continue amid early commercialization phase.
- Gross margin remains variable due to product mix.
- U.S. life sciences market impacted by NIH funding uncertainty.
- Adjusted EBITDA loss widened slightly YoY.
- No upward revisions to revenue outlook were issued.
Revenue & Expenses
Visualization of income flow from segment revenue to net income